Praveen Kumar Marimuthu, DM Resident in Medical Oncology at Christian Medical College and Hospital , shared a post on X:
“Low-grade Serous Ovarian Ca (LGSOC)
- Primary surgery preferred
- Sometimes misdiagnosed on pathology as Serous Borderline Tumor / HGSOC
- Consider post-op imaging
- Consider molecular testing – MAPK pathway alterations – BRAF/RAS mut seen in some patients
- Expected ORR with chemo: ~10–25%
- NRG-GY019 results due June 2025 – will answer: Pacli+Carbo x6 and Letrozole maintenance vs Letrozole alone for Stage II–IV LGSOC
- Chemo + Bevacizumab combo is underutilized – better ORR (possible better PFS) vs chemo alone
- NACT is not recommended (ORR ~10%)
- Neoadjuvant fulvestrant + abemaciclib showed ORR 60% in a pilot study
- Single-agent MEKi: ~20% ORR, 1-year median PFS in MAPK-altered patients; 1/3 discontinue due to toxicity
- Future directions:
- Avutomerinib (RAF/MEK) + Defactinib (FAKi) – ORR 42% (especially in KRASmut) – Phase II ongoing
More posts featuring Praveen Kumar Marimuthu.